#1 Clinical Trials Search in Europe

Fitusiran

Fitusiran is an investigational drug being studied in clinical trials for the treatment of hemophilia A and B, with or without inhibitors. This novel therapy aims to prevent bleeding episodes in patients with severe hemophilia by targeting antithrombin, a protein that regulates blood clotting. The clinical trials are evaluating the safety, efficacy, and long-term effects of fitusiran compared to standard treatments like factor replacement therapy or bypassing agents.

Table of Contents

What is Fitusiran?

Fitusiran is a new medication being developed to treat hemophilia, a rare bleeding disorder. It’s also known by its research name SAR439774[1]. Fitusiran is different from traditional hemophilia treatments because it works in a new way to help prevent bleeding episodes in people with this condition[2].

How Does Fitusiran Work?

Fitusiran works by targeting a protein in the body called antithrombin (AT). In people with hemophilia, lowering the amount of AT can help the blood clot more easily. This is important because hemophilia causes problems with blood clotting, which can lead to excessive bleeding[3].

The medication helps to reduce AT levels in the body, which in turn increases the body’s ability to form blood clots when needed. This can help prevent or reduce bleeding episodes in people with hemophilia[4].

What Conditions Does Fitusiran Treat?

Fitusiran is being studied to treat two main types of hemophilia:

  • Hemophilia A: This is the most common type of hemophilia, caused by a lack of blood clotting factor VIII.
  • Hemophilia B: This is a less common type, caused by a lack of blood clotting factor IX.

Fitusiran is being tested in people with severe forms of these conditions, both with and without inhibitors. Inhibitors are antibodies that some people with hemophilia develop, which can make traditional treatments less effective[5].

How is Fitusiran Administered?

Fitusiran is given as a subcutaneous injection, which means it’s injected just under the skin. In clinical trials, it’s being tested with different dosing schedules:

  • Once a month (monthly dosing)
  • Once every two months (every other month dosing)

The exact dosing schedule may depend on the individual patient and their doctor’s recommendations[6].

Clinical Trials and Effectiveness

Fitusiran is currently being studied in several clinical trials to test its safety and effectiveness. These trials are looking at how well fitusiran works to prevent bleeding episodes in people with hemophilia[7].

Some key points from the clinical trials include:

  • Researchers are measuring the annualized bleeding rate (ABR), which is the number of bleeding episodes a person experiences in a year. Early results suggest that fitusiran may help reduce the number of bleeding episodes compared to other treatments[8].
  • The trials are also looking at spontaneous bleeding (bleeding that occurs without an obvious cause) and joint bleeding, which are common problems in hemophilia[4].
  • Some studies are comparing fitusiran to current standard treatments, including both on-demand treatment (where medication is given when bleeding occurs) and prophylaxis (regular treatment to prevent bleeding)[6].

Potential Side Effects

As with any medication, fitusiran may cause side effects. The clinical trials are carefully monitoring participants for any adverse events (unwanted or harmful effects). Some potential areas of concern include:

  • Changes in liver function
  • Risks related to blood clotting
  • Injection site reactions

It’s important to note that the full range of potential side effects may not be known until more people have used the medication over a longer period of time[2].

Quality of Life Improvements

In addition to measuring how well fitusiran prevents bleeding, researchers are also interested in how it affects patients’ quality of life. They’re using questionnaires to assess things like:

  • Physical health and ability to do daily activities
  • Pain levels
  • Overall satisfaction with treatment
  • Joint health

These measures help researchers understand not just the medical effects of fitusiran, but also how it impacts patients’ everyday lives[7].

Aspect Details
Drug Name Fitusiran (also known as SAR439774)
Condition Treated Hemophilia A and B, with or without inhibitors
Mechanism of Action Reduces antithrombin levels to rebalance clotting system
Administration Subcutaneous injection, monthly or every two months
Primary Outcome Measure Annualized Bleeding Rate (ABR)
Trial Phases Phase 1 to Phase 3
Trial Durations 9 months to 3 years, with additional follow-up
Key Secondary Outcomes Safety, quality of life, antithrombin levels, thrombin generation
Patient Populations Adults and adolescents (≥12 years old in some trials)
Comparators On-demand treatment, factor prophylaxis, bypassing agents

FAQ

  • What is fitusiran and how does it work? Fitusiran is an investigational drug that works by reducing levels of antithrombin, a protein that inhibits blood clotting. By lowering antithrombin, fitusiran aims to rebalance the clotting system in people with hemophilia and prevent bleeding episodes.
  • How is fitusiran administered? Fitusiran is given as a subcutaneous (under the skin) injection, typically once a month or once every two months, depending on the specific trial protocol.
  • What types of hemophilia is fitusiran being studied for? Fitusiran is being studied in clinical trials for both hemophilia A and hemophilia B, including patients with and without inhibitors to factor VIII or IX.
  • What are the main outcomes being measured in fitusiran clinical trials? The main outcomes include the annualized bleeding rate (how often patients experience bleeding episodes per year), safety and tolerability, quality of life measures, and changes in laboratory values like antithrombin levels and thrombin generation.
  • How long do the fitusiran clinical trials last? The duration of fitusiran clinical trials varies, but many last between 9 months to 3 years for the treatment period, with additional follow-up time to monitor antithrombin levels after treatment ends.

Ongoing Clinical Trials on Fitusiran

  • A study testing fitusiran to prevent bleeding in boys aged 1 to 11 years with hemophilia A or B with or without inhibitors

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Germany Hungary Italy Poland Romania +1

  • Study of Long-term Safety and Efficacy of Fitusiran in Patients with Hemophilia A or B with or without Inhibitory Antibodies to Factor VIII or IX

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark France Hungary Ireland Italy

  • Study of Fitusiran for Preventing Bleeding in Boys Aged 1 to 12 with Hemophilia A or B

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy Spain

  • Study on Fitusiran for Preventing Bleeding in Males Aged 12 and Older with Severe Hemophilia A or B, with or without Inhibitors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Greece Italy Poland Spain

Glossary

  • Antithrombin (AT): A protein in the blood that helps regulate clotting by inhibiting several clotting factors. Fitusiran works by reducing antithrombin levels.
  • Annualized Bleeding Rate (ABR): A measure of how many bleeding episodes a person with hemophilia experiences in a year, used to assess the effectiveness of treatments.
  • Bypassing Agent (BPA): A type of treatment used for hemophilia patients with inhibitors that 'bypasses' the need for the missing clotting factor.
  • Factor Concentrate: A treatment that contains the specific clotting factor (VIII or IX) that is missing or low in people with hemophilia.
  • Hemophilia A: A genetic disorder caused by a deficiency in clotting factor VIII.
  • Hemophilia B: A genetic disorder caused by a deficiency in clotting factor IX.
  • Inhibitors: Antibodies that the immune system develops against treatment with clotting factors, making them less effective.
  • Prophylaxis: Regular treatment to prevent bleeding episodes in people with hemophilia.
  • Subcutaneous Injection: An injection given under the skin, which is how fitusiran is administered.
  • Thrombin Generation: A laboratory test that measures the ability of blood to form clots, used to assess the effectiveness of fitusiran treatment.

References

  1. https://clinicaltrials.gov/study/NCT03974113
  2. https://clinicaltrials.gov/study/NCT03754790
  3. https://clinicaltrials.gov/study/NCT02554773
  4. https://clinicaltrials.gov/study/NCT03417245
  5. https://clinicaltrials.gov/study/NCT03417102
  6. https://clinicaltrials.gov/study/NCT03549871
  7. https://clinicaltrials.gov/study/NCT06145373
  8. https://clinicaltrials.gov/study/NCT05662319